Literature DB >> 7559491

Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures.

R Chignola1, C Anselmi, M Dalla Serra, A Franceschi, G Fracasso, M Pasti, E Chiesa, J M Lord, G Tridente, M Colombatti.   

Abstract

A chimeric protein was obtained by fusing together the ricin toxin A chain (RTA) gene and a DNA fragment encoding the N terminus of protein G of the vesicular stomatitis virus. Chimeric RTA (cRTA) retained full enzymic activity in a cell-free assay, but was 10-fold less toxic against human leukemic cells than either native RTA (nRTA) or unmodified recombinant RTA (rRTA). However, conjugates made with cRTA and human transferrin (Tfn) showed 10-20-fold greater cell killing efficacy than Tfn-nRTA or Tfn-rRTA conjugates despite equivalent binding of the three conjugates to target tumor cells. As a consequence, by fusion of the KFT25 peptide to the RTA sequence, the specificity factor (i.e. the ratio between nonspecific and specific cytotoxicity) of Tfn-cRTA was increased 90-240 times with respect to those of Tfn-nRTA and Tfn-rRTA. cRTA interacted with phospholipid vesicles with 15-fold faster kinetics than nRTA at acidic pH. Taken together, our results suggest that the ability of vesicular stomatitis virus protein G to interact with cell membranes can be transferred to RTA to facilitate its translocation to the cell cytosol. Our strategy may serve as a general approach for potentiating the cytotoxic efficacy of antitumor immunotoxins.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7559491     DOI: 10.1074/jbc.270.40.23345

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.

Authors:  D Castelletti; G Fracasso; S Righetti; G Tridente; R Schnell; A Engert; M Colombatti
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

2.  Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy.

Authors:  Hetal Pandya; Waldemar Debinski
Journal:  BioDrugs       Date:  2012-08-01       Impact factor: 5.807

Review 3.  Enhancement of immunotoxin activity using chemical and biological reagents.

Authors:  M Wu
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

Review 4.  Ribosome-inactivating proteins: from plant defense to tumor attack.

Authors:  Maddalena de Virgilio; Alessio Lombardi; Rocco Caliandro; Maria Serena Fabbrini
Journal:  Toxins (Basel)       Date:  2010-11-10       Impact factor: 4.546

Review 5.  Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.

Authors:  Roger Gilabert-Oriol; Alexander Weng; Benedicta von Mallinckrodt; Matthias F Melzig; Hendrik Fuchs; Mayank Thakur
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

6.  Augmentation of Saporin-Based Immunotoxins for Human Leukaemia and Lymphoma Cells by Triterpenoid Saponins: The Modifying Effects of Small Molecule Pharmacological Agents.

Authors:  Wendy S Smith; David A Johnston; Suzanne E Holmes; Harrison J Wensley; Sopsamorn U Flavell; David J Flavell
Journal:  Toxins (Basel)       Date:  2019-02-20       Impact factor: 4.546

7.  A Flow Cytometric Method to Quantify the Endosomal Escape of a Protein Toxin to the Cytosol of Target Cells.

Authors:  Harrison J Wensley; David A Johnston; Wendy S Smith; Suzanne E Holmes; Sopsamorn U Flavell; David J Flavell
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

Review 8.  Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers.

Authors:  Hendrik Fuchs; Alexander Weng; Roger Gilabert-Oriol
Journal:  Toxins (Basel)       Date:  2016-07-01       Impact factor: 4.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.